New NLRP3 Inhibitor BGE-102 Slashes Inflammation Markers by 85% in Phase 1 Trial
BioAge's oral drug BGE-102 cut a key cardiovascular risk biomarker by up to 86% in obese patients, rivaling higher doses at just 60mg daily.
Summary
BioAge Labs has reported promising Phase 1 results for BGE-102, an oral pill that blocks the NLRP3 inflammasome — a key driver of chronic inflammation linked to heart disease, metabolic disorders, and aging. In participants with obesity and elevated inflammation, a 60mg daily dose reduced high-sensitivity C-reactive protein (hsCRP) by up to 86% over 21 days, with 87% of treated participants reaching healthy hsCRP levels below 2 mg/L. The drug was well-tolerated and showed effects comparable to a higher 120mg dose. BioAge plans to launch a Phase 2 cardiovascular trial in early 2026, with results expected later that year. If the drug continues to perform, it could become a significant tool for reducing cardiovascular and age-related inflammatory disease.
Detailed Summary
Chronic low-grade inflammation is one of the most well-established drivers of aging-related disease, from cardiovascular events to neurodegeneration. A key molecular trigger of this inflammation is the NLRP3 inflammasome, a protein complex that, when overactivated, fuels systemic inflammatory damage. BioAge Labs has developed BGE-102, an oral, brain-penetrant small molecule designed to inhibit NLRP3 — and its Phase 1 results are drawing significant attention.
In the trial's most notable cohort, participants with obesity and elevated baseline inflammation received 60mg of BGE-102 once daily for 21 days. The drug produced an 85% reduction in hsCRP by Day 7, sustaining an 86% reduction by Day 21. Critically, 87% of active-treatment participants achieved hsCRP below 2 mg/L — a threshold associated with a 25% reduction in major adverse cardiovascular events in prior anti-inflammatory intervention studies. A higher 120mg dose produced comparable results over 14 days, suggesting the lower dose may be sufficient.
Beyond hsCRP, BGE-102 reduced multiple inflammatory biomarkers consistently, and the drug demonstrated brain penetration — a rare and potentially valuable property for addressing neuroinflammation in CNS diseases. BioAge's CMO compared the drug's potential impact to that of statins for LDL cholesterol, positioning NLRP3 inhibition as a possible new pillar of cardiovascular and longevity medicine.
For health-conscious individuals, this research highlights the growing clinical importance of hsCRP as a trackable biomarker and inflammation as a modifiable risk factor. While BGE-102 is not yet available, the trial validates NLRP3 as a high-value therapeutic target.
Important caveats apply: this is Phase 1 data focused on safety and pharmacokinetics, not clinical outcomes. The cohorts were small, and long-term efficacy and safety remain unproven. Phase 2 cardiovascular outcome data, expected in late 2026, will be the next critical test.
Key Findings
- BGE-102 reduced hsCRP by up to 86% at 60mg daily over 21 days in obese participants with elevated inflammation.
- 87% of treated participants achieved hsCRP below 2 mg/L, a level linked to 25% fewer major cardiovascular events.
- The 60mg dose matched the efficacy of the 120mg dose, suggesting a lower effective therapeutic threshold.
- BGE-102 is brain-penetrant, opening potential applications in neuroinflammation and CNS diseases beyond cardiovascular risk.
- Phase 2 cardiovascular proof-of-concept trial planned for H1 2026, with results anticipated by end of 2026.
Methodology
This is a news report summarizing a company-issued press release on Phase 1 clinical trial results from BioAge Labs, published by Lifespan.io, a credible longevity-focused science outlet. The trial was randomized, double-blind, and placebo-controlled, lending methodological credibility, though the data has not yet been peer-reviewed or published in a journal.
Study Limitations
Phase 1 trials are primarily designed to assess safety and pharmacokinetics, not clinical efficacy outcomes, so these results do not yet confirm disease prevention or mortality benefits. Cohort sizes were small and the dosing period was short (14–21 days), limiting conclusions about long-term effects. Full peer-reviewed publication and Phase 2 outcome data are needed before drawing firm clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.